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Abstract
 
Although coinfection of hepatitis B virus (HBV) and 
 
Schistosoma
 
 
 
mansoni
 
 is a frequent event in
humans, little is known about the interactions between these two pathogens. 
 
S
 
. 
 
mansoni
 
 infec-
tion induces T helper cell type 2 (Th2)–type cytokines in the liver of humans and mice. The
intrahepatic induction of nitric oxide (NO) and Th1-type cytokines, such as interferon (IFN)-
 
g
 
and IFN-
 
a
 
/
 
b
 
, inhibits HBV replication noncytopathically in the liver of transgenic mice. To
examine whether 
 
S
 
. 
 
mansoni
 
 infection and the accompanying induction of Th2-type cytokines
could interfere with HBV replication in the liver, HBV transgenic mice were infected with 
 
S
 
.
 
mansoni
 
. By 5 wk after infection, HBV replication disappeared concomitant with the intrahe-
patic induction of NO and Th1-type cytokines, and in the absence of Th2-type cytokines. By
6–8 wk after infection, HBV replication remained undetectable and this was associated with
further induction of NO and Th1-type cytokines together with the appearance of Th2-type
cytokines. The 
 
S
 
. 
 
mansoni
 
–dependent antiviral effect was partially blocked by genetically delet-
ing IFN-
 
g
 
, although it was unaffected by deletion of IFN-
 
a
 
/
 
b
 
. These results indicate that
IFN-
 
g
 
 (probably via NO) mediates most of this antiviral activity and that Th2-type cytokines
do not counteract the antiviral effect of IFN-
 
g
 
. Similar events may suppress HBV replication
during human 
 
S
 
. 
 
mansoni
 
 infection.
Key words: transgenic/knockout • infectious immunity virus • helminth parasites • Th1/Th2 
cytokines • liver
 
Introduction
 
Hepatitis B virus (HBV) is a noncytopathic, double-
stranded DNA virus that causes acute and chronic hepatitis
and hepatocellular carcinoma in humans (1). It is widely
believed that the cytotoxic T cell (CTL) response to the vi-
rus plays a critical role in viral clearance and liver disease.
Indeed, the CTL response is strong, polyclonal, and multi-
specific during acute HBV infection, but is usually unde-
tectable in patients with chronic hepatitis (1). Using a
transgenic mouse model, we have shown recently that the
antiviral potential of the CTLs is primarily mediated by
noncytolytic mechanisms that involve the intrahepatic pro-
duction of Th1-type cytokines such as IFN-
 
g
 
 (2, 3). We
also showed that nitric oxide (NO) mediates most of the
antiviral activity of IFN-
 
g
 
 produced by the CTLs and that
IFN-
 
a
 
/
 
b
 
 produced in the liver during unrelated hepato-
tropic virus infections inhibits HBV replication via NO-
independent pathways (3–6). Noncytopathic antiviral
mechanisms like these can contribute to viral clearance
during acute viral hepatitis in chimpanzees, thus confirming
the transgenic mouse studies in a natural infection model
(7). All these events occur in the liver in the absence of
Th2-type cytokines such as IL-4, IL-5, and IL-10.
Whether the outcome of HBV infection in humans (viral
clearance versus viral persistence) is influenced by qualita-
tive differences in the intrahepatic cytokine profile (Th1-
type versus Th2-type) is not known.
 
Schistosoma
 
 
 
mansoni
 
 is a helminth parasite (class Trema-
toda) that infects both humans and mice. Schistosomiasis
affects more than 200 million people worldwide, particu-
larly in Africa, Asia, and South America, areas in which
chronic HBV infection is endemic. Schistosomiasis is
largely dependent on the abundance of the snail intermedi-
ate host. Infection begins when cercariae shed into the wa-
ter by infected snails penetrate the skin of individuals ex-
posed to contaminated water. After penetration, the larvae
enter the microcirculation and reach the hepatic portal sys-
tem where they remain. After several weeks of infection,
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the female worm deposits a large number of eggs, leading
to the formation of granulomas in the liver (8). The patho-
genesis of egg granuloma formation involves a Th2-type
cytokine response that begins few days after egg laying with
production of increasing levels of IL-4, IL-5, and IL-10 by
Th2 cells, eosinophils, and basophils (8, 9). In experimen-
tally infected mice, the Th2-type cytokine response peaks
on week 8 after infection, and this process is thought to
downregulate the secretion of Th1-type cytokines (includ-
ing TNF-
 
a
 
 and IFN-
 
g
 
) that peaks few weeks earlier
(weeks 4–5) (8, 9). This shift in cytokine profile may ini-
tiate the chronic stage of infection and contribute to the
amelioration of liver pathology by inhibiting the continu-
ous production of potentially harmful inflammatory media-
tors (8, 9).
Although coinfection of HBV and 
 
S
 
. 
 
mansoni
 
 is a fre-
quent event in several geographic areas of the world, very
little is known about the possible interactions between
these two pathogens. In this study we took advantage of
transgenic mice that replicate HBV at high levels in the
liver to directly examine whether 
 
S
 
. 
 
mansoni
 
 infection and
the accompanying induction of Th2-type cytokines could
modulate HBV replication. Thus, we monitored HBV rep-
lication in HBV transgenic mice that were infected with 
 
S
 
.
 
mansoni
 
 and we compared these results with those obtained
in 
 
S
 
. 
 
mansoni
 
–infected HBV transgenic mice genetically de-
ficient for IFN-
 
g
 
 or IFN-
 
a
 
/
 
b
 
 receptor.
 
Materials and Methods
 
HBV Transgenic Mice.
 
HBV transgenic mice from lineage
1.3.32 (inbred C57BL/6, official designation Tg[HBV 1.3 ge-
nome]Chi32) and lineage 1.3.46 (inbred B10D2, official designa-
tion Tg [HBV 1.3 genome]Chi46) were used in this study. Lin-
eages 1.3.32 and 1.3.46 replicate high levels HBV in their livers
without any evidence of cytopathology, as previously described
(10). Lineage 1.3.46 was backcrossed against knockout mice that
lack IFN-
 
g
 
 (IFN-
 
g
 
2
 
/
 
2
 
) (11) and the IFN-
 
a
 
/
 
b
 
 receptor (IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
) (12), as previously described (3). The knockout mice
were provided by Drs. Timothy Stewart (IFN-
 
g
 
2
 
/
 
2
 
) and Michel
Aguet (IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
) at Genentech, South San Francisco, CA.
The genetic background of the original parental lineages of IFN-
 
g
 
2
 
/
 
2
 
 and IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
 were 129/Sv/Ev/ 
 
3
 
 C57BL/6. The
IFN-
 
g
 
2
 
/
 
2
 
 mice were backcrossed four to five generations against
BALBc and the IFN-
 
a
 
/
 
b
 
R
 
2
 
/
 
2
 
 mice were backcrossed more than
five generations against C57BL/6 before they were mated with
lineage 1.3.46 (inbred B10D2). F
 
1 
 
progeny were interbred to
yield hepatitis B e antigen-positive (HBeAg) F
 
2
 
 progeny that
were either homozygous or heterozygous for the null mutation.
In all experiments, the mice were matched for age (8 wk), sex
(male), and HBeAg levels in their serum before experimental ma-
nipulations. All animals were housed in pathogen-free rooms un-
der strict barrier conditions.
 
Infection of Mice with S. mansoni.
 
8-wk-old HBV transgenic
male mice were infected by percutaneous exposure of tail skin for
60 min in water containing 20–25 cercariae, as previously de-
scribed (13). Mice were killed at different weeks after infection
and their livers were harvested for histological and histochemical
analyses, or they were snap frozen in liquid nitrogen and stored at
 
2
 
80
 
8
 
C for subsequent molecular analyses (see below).
Figure 1. Inhibition of HBV replication during S. mansoni infection.
Age-, sex-, and serum HBeAg–matched transgenic mice from lineage
1.3.32 were exposed to water containing cercariae and killed on weeks 5,
6, 7, and 8 after exposure. Total hepatic DNA was analyzed for HBV
DNA by Southern blot (SB) analysis. All DNA samples were RNAse
treated before gel electrophoresis. Bands corresponding to the integrated
transgene (Transg.), relaxed-circular (RC), and single-stranded (SS) linear
HBV DNA replicative forms are indicated. The integrated transgene can
be used to normalize the amount of DNA bound to the membrane. The
filter was hybridized with a 32P-labeled HBV-specific DNA probe. Total
hepatic RNA was analyzed for the message of 2959 OAS and GAPDH by
Northern blot (NB) analysis and for the message of iNOS, various cyto-
kine transcripts, CD3, CD4, CD8, F480, and NK1.1 by RNase Protec-
tion assay (RPA), as indicated. The mRNA encoding the ribosomal pro-
tein L32 was used to normalize the amount of RNA loaded in each lane
of the RPA assay. Results were compared with those observed in livers
pooled from six age-, sex-, and serum HBeAg–matched, saline-injected
transgenic controls (time 0). The mean sALT activity, measured at the
time of autopsy, is indicated at the bottom for each group and is expressed
in units per liter. 
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HBV replication in the liver of transgenic mice, four
groups (six mice per group) of age- (8 wk), sex- (male), and
serum HBeAg–matched transgenic mice from lineage
1.3.32 (inbred C57BL/6) were exposed to water contain-
ing cercariae and killed on weeks 5, 6, 7, and 8 after expo-
sure. All animals were successfully infected as indicated by
the presence of adult worms, eggs, and granulomas in the
liver (see below).
Since each mouse in each group of six mice showed
identical results, two representative mice per group are
shown in Fig. 1. On week 5 after infection, HBV DNA
replicative forms completely disappeared from the liver of
transgenic mice when compared with saline-injected con-
trols (Fig. 1). At this time point, the messages for the T cell
markers CD3, CD4, and CD8, the macrophage marker
F4-80, and the NK cell marker NK1.1 were induced, indi-
cating that granulomas were already present in the liver, as
confirmed by histological analysis (data not shown). De-
spite the presence of granulomas, no hepatocellular lysis
was observed at this time, as underscored by the absence
of serum ALT elevation (Fig. 1, bottom). The intrahepatic
cytokine profile was markedly directed towards a type 1 re-
sponse, as indicated by the induction of iNOS, TNF-
 
a
 
, IL-
1-
 
a
 
, IFN-
 
g
 
, IL-1-
 
b
 
, and TGF-
 
b
 
. Furthermore, the messages
for Th2-type cytokines were either not (IL-4 and IL-5) or
barely (IL-10) induced (Fig. 1).
By weeks 6, 7, and 8 after infection, hepatic granulomas
(Fig. 2 B) increased in number and size (data not shown)
 
Tissue DNA and RNA Analyses.
 
Frozen liver tissue was me-
chanically pulverized under liquid nitrogen and total genomic DNA
and RNA were isolated for Southern and Northern blot analyses ex-
actly as previously described (10). Nylon membranes were analyzed
for HBV DNA, 2
 
9
 
5
 
9
 
-oligoadenylate synthetase (2
 
9
 
5
 
9
 
-OAS) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as previ-
ously described (4). Quantitation of inducible NO synthase (iNOS),
cytokine, and T lymphocyte, macrophage, and NK cell marker
mRNAs was performed by RNase protection assay exactly as
previously described (6). The relative abundance of specific DNA
and RNA molecules was quantitated by phosphorimaging analysis,
using the Optiquant™ image analysis software (Packard Instru-
ment Co.).
 
Biochemical, Histological, and Immunohistochemical Analyses.
 
Mea-
suring serum alanine aminotransferase (sALT) activity at multiple
time points after infection with 
 
S
 
.
 
 mansoni
 
 monitored the extent
of hepatocellular injury. sALT activity was measured in a Para-
max chemical analyzer (Baxter Diagnostics Inc.), exactly as previ-
ously described (14). For histological analysis, liver tissue samples
were fixed in 10% zinc-buffered formalin (Anatech), embedded
in paraffin, sectioned (3 
 
m
 
m), and stained with hematoxylin and
eosin exactly as described elsewhere (14). The intracellular distri-
bution of hepatitis B core antigen (HBcAg) was assessed by the
Labeled Avidin-Biotin (LAB; Dako) detection procedure exactly
as previously described (14).
 
Results and Discussion
 
Inhibition of HBV Replication during S. mansoni Infection.
 
To determine whether 
 
S
 
. 
 
mansoni
 
 infection could modulate
Figure 2. Intracellular localization of HBcAg in wild-type and IFN-g–deficient HBV transgenic mice during S. mansoni infection. Age-, sex-, and se-
rum HBeAg–matched transgenic mice from lineage 1.3.46 that were either heterozygous (1/2) or homozygous (2/2) for the IFN-g null mutations were
exposed to water containing cercariae and killed on week 8 after exposure. Liver sections obtained from uninfected HBV-IFN-g1/2 mice, S. mansoni–
infected HBV–IFN-g1/2 or HBV–IFN-g2/2 mice were stained for the presence of HBcAg. Note that in uninfected HBV–IFN-g1/2 mice (A), cyto-
plasmic HBcAg is mainly detectable in centrilobular hepatocytes surrounding the central veins (top). These are the cells that sustain high levels of HBV
replication. Also note that cytoplasmic HBcAg disappeared from centrilobular hepatocytes of S. mansoni–infected HBV-IFN-g1/2 (B) and was still de-
tectable in the cytoplasm of centrilobular hepatocytes of S. mansoni–infected HBV–IFN-g2/2 mice (C). Adult worms (asterisk) and eggs (arrowheads) are
indicated. Immunoperoxidase stain for HBcAg, original magnification: 3200.292 Schistosoma-dependent Inhibition of HBV Replication
and HBV replication remained suppressed. Since viral rep-
lication occurs inside of HBcAg-positive nucleocapsid par-
ticles in the cytoplasm of centrilobular hepatocytes (Fig. 2
A) in these transgenic mice (10), it is not surprising that
HBcAg disappeared from the cytoplasm of these cells (Fig.
2 B), along with the disappearance of HBV replicative
forms (Fig. 1). The intrahepatic expression of iNOS, Th1-
type cytokines, and T lymphocyte, macrophage, and NK
cell markers progressively increased, reaching its peak by
week 8 after infection. This was accompanied by the in-
duction of Th2-type cytokines (IL-4, IL-5, and IL-10) that
started by week 6 and also peaked by week 8 (Fig. 1).
These results were somewhat surprising since others have
reported that the peak of Th2-type cytokine response after
S. mansoni infection in mice (week 8) coincides with the
downregulation of Th1-type cytokines (for review see ref-
erence 8). Using a quantitative assay (RNase Protection) to
measure the intrahepatic content of cytokine messages, we
confirmed in this study that Th2-type cytokines peaked on
week 8, but this did not coincide with any waning of the
type 1 immune response in the liver, which also peaked by
week 8 (Fig. 1).
No induction of 2959-OAS (a marker of IFN-a/b in-
duction) was detected throughout the infection, indicating
that IFN-a/b is not produced in the liver of S. mansoni–
infected animals. sALT activity slightly increased by week
6, peaked at week 7, and started to decline by week 8 (Fig.
1, bottom). Given the relatively low levels of sALT, the
extent of hepatocellular lysis in these animals was moderate
throughout the infection.
Groups of HBV transgenic mice (three mice per group)
were also killed during the chronic stage of infection
(weeks 10 and 12). The number of hepatic granulomas de-
creased, Th1-type and Th2-type cytokines were still in-
duced in the liver (although to lower levels compared with
week 8), and HBV replication remained downregulated
(data not shown). Finally, similar results were obtained
when groups (four mice per group) of age- (8 wk), sex-
(male), and serum HBeAg–matched transgenic mice from
lineage 1.3.46 (inbred B10D2) were infected with S. man-
soni and killed at 5, 6, 7, 8, and 12 wk after exposure (data
not shown). This indicates that these results are highly re-
producible and they are not affected by the genetic back-
ground of the mice.
Taken together, the data indicate that during S. mansoni
infection the intrahepatic cytokine profile is initially of a
Th1-type and this is associated with the noncytopathic in-
hibition of HBV replication. In the following weeks, de-
spite the fact that both Th1- and Th-2 type cytokines are
induced in the liver, HBV replication remains abolished.
Suppression of HBV Replication during S. mansoni Infection
Is Mostly Mediated by IFN-g. Since we have previously
identified IFN-g and IFN-a/b as two cytokines capable of
downregulating HBV replication noncytopathically in the
liver of transgenic mice (3, 4, 14), we monitored the ability
of S. mansoni infection to inhibit HBV replication in trans-
genic mice that were unable to produce IFN-g or the
receptor for IFN-a/b. Groups of age-, sex-, and HBeAg-
matched transgenic mice (six mice per group) that were ei-
ther homozygous (2/2) or heterozygous (1/2) for these null
mutations were exposed to water containing cercariae and
killed on week 8 after exposure.
As shown in Fig. 3 for three representative mice per
group, HBV DNA replicative forms disappeared from the
Figure 3. Suppression of HBV replication by S. mansoni infection is
mostly mediated by IFN-g. Age-, sex-, and serum HBeAg–matched
transgenic mice from lineage 1.3.46 that were either heterozygous (1/2)
or homozygous (2/2) for the IFN-g and the IFN-a/b receptor null mu-
tations were exposed to water containing cercariae and killed on week 8
after exposure. Total hepatic DNA was analyzed for HBV DNA by
Southern blot (SB) analysis. All DNA samples were RNAse treated before
gel electrophoresis. Bands corresponding to the integrated transgene
(Transg.), relaxed-circular (RC), and single-stranded (SS) linear HBV
DNA replicative forms are indicated. The integrated transgene can be
used to normalize the amount of DNA bound to the membrane. The fil-
ter was hybridized with a 32P-labeled HBV-specific DNA probe. Total
hepatic RNA was analyzed for the message of 2959 OAS and GAPDH by
Northern blot (NB) analysis and for the message of iNOS, various cyto-
kine transcripts, CD3, CD4, CD8, F480, and NK1.1 by RNase Protection
assay (RPA), as indicated. The mRNA encoding the ribosomal protein
L32 was used to normalize the amount of RNA loaded in each lane of
the RPA assay. Results were compared with those observed in livers
pooled from six age-, sex-, and serum HBeAg–matched, saline-injected
transgenic controls (time 0). The mean sALT activity, measured at the
time of autopsy, is indicated at the bottom for each group and is expressed
in units per liter.293 McClary et al. Brief Definitive Report
liver of all of the heterozygous mice, coinciding with in-
duction of iNOS, Th1- and Th2-type cytokines, and T
lymphocyte, macrophage, and NK cell markers. Similarly,
HBV replication was abolished in the liver of IFN-a/bR2/2
mice, indicating that IFN-a/b does not contribute to the
antiviral effect of S. mansoni infection. This is compatible
with the fact that 2959-OAS was not induced in the S. man-
soni–infected livers (Figs. 1 and 3).
In contrast, HBV replication was only partially reduced
in the IFN-g knockout animals (Fig. 3), indicating that
IFN-g mediates most of the antiviral activity of S. mansoni
infection. It is noteworthy that the hepatic levels of HBV
replicative forms were quite variable among different indi-
viduals (the variability in HBV DNA content extended to
three additional mice that are not shown in Fig. 3). The
reason for this variability remains to be determined. Never-
theless, HBV DNA remained detectable in all IFN-g2/2
mice and, in keeping with this, HBcAg also remained de-
tectable in the cytoplasm of hepatocytes, even in those that
were directly adjacent to hepatic granulomas (Fig. 2 C).
Interestingly, the intrahepatic content of iNOS mRNA
was markedly reduced in the liver of IFN-g2/2 mice (ap-
proximately fivefold, as measured by phosphorimaging
analysis; data not shown), as compared with the liver of all
the other S. mansoni–infected mice (Fig. 3). The fact that
IFN-g2/2 mice showed reduced intrahepatic levels of
iNOS at this time point suggests that NO may have con-
tributed to the antiviral effect of IFN-g in this system. This
would be consistent with a previous report from our labo-
ratory where it was shown that virus-specific CTLs can
abolish HBV replication in the hepatocytes of transgenic
mice by IFN-g–dependent mechanisms that involve NO
(6). Additionally, IFN-g and NO may also exert a protec-
tive role during S. mansoni infection, since mice genetically
deficient for IFN-g showed the lowest levels of iNOS and
the highest levels of sALT activity (Fig. 3). Similar findings
have been reported recently in a study by Brunet et al.,
where treatment of S. mansoni–infected mice with iNOS
inhibitors increased the severity of liver disease (15).
Very few (and contradictory) studies describing possible
interactions between HBV and S. mansoni are available.
Although some studies have shown little or no epidemio-
logical association between S.  mansoni  infection and the
presence of antibody to hepatitis B virus core antigen (anti-
HBc) and hepatitis B surface antigen (HBsAg) (16–19),
others have shown that concurrence of these two infections
correlates with a more severe liver disease and a longer per-
sistence of HBsAg (20, 21). Based on the results of this re-
port, it is possible that Th1-type cytokines may inhibit
HBV replication during human S. mansoni infection, irre-
spective of the presence of Th2-type cytokines in the liver.
The results shown here also suggest that the presence of
Th2-type cytokines do not counteract the antiviral activity
of IFN-g. This could be important for the pathogenesis of
HBV infection in humans. It has been postulated that the
outcome of HBV infection (viral clearance versus viral per-
sistence) may be influenced by qualitative differences in the
intrahepatic cytokine profile (Th1-type versus Th2-type)
(22). Indirect evidence has suggested that persistence of
HBV may be associated with a predominant Th2-type re-
sponse. This is because the titer of antibody in the serum of
chronically infected patients (in which the cellular immune
response is absent or extremely weak) is higher than that of
acutely infected patients who cleared the virus (in which
cellular immune response is relatively strong) (22). Along
these lines, it was recently shown that most liver-infiltrating
T cells in chronic hepatitis B infection in humans have a
Th0-like phenotype, since they are able to produce IFN-g,
IL-4, and IL-5 (23). The results of this study indicate that
IFN-g inhibits HBV replication in the presence of IL-4,
IL-5, and IL-10. Therefore, it is possible that persistence of
HBV may primarily result from a quantitative deficiency of
Th1-type responses rather than qualitative differences in
the intrahepatic cytokine profile. Accordingly, it has been
shown recently that the number of IFN-g–producing anti-
gen-specific T cells isolated from the peripheral blood of
people chronically infected with HBV is much lower than
that observed in the peripheral blood of people acutely in-
fected with HBV (24).
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